2805 Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): An updated analysis. (September 2015) - Guo, M.; Sherman, S.; Wirth, L.; Schlumberger, M.; Dutcus, C.; Robinson, B.; Tahara, M.; Latimer, N.